Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Enliven Therapeutics, Inc.

ELVN · Nasdaq · CIK 0001672619 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

55 Form 4 transaction lines observed in the same window
42 sales · 13 option, withholding, award, gift or other lines

Last qualifying purchase2023-02-23 · COMMODORE CAPITAL LP · $13.7K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesHigh
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Collins Helen LouiseCHIEF MEDICAL OFFICER
○▼○▼○▼○▼○▼
Hohl BenjaminCHIEF FINANCIAL OFFICER
○▼○▼▼○▼
Derynck Mika KDirector
○▼
ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLCTenPercentOwner
▼▼
Kunkel Lori AnneDirector
▼▼
Garland J. ScottDirector
○▼
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2023-02-23 · COMMODORE CAPITAL LP.

Recent Form 4 activity

0Purchases
75Sales
25Other Form 4 lines
40SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING42 sale line(s) · context only
OTHER13 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
10,356,282
Previous report
8,620,503
Avg daily volume
1,887,497
Days to cover
5.5

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2023-02-23COMMODORE CAPITAL LPPurchase (P)Common stock, par value $0.001 per share622USD 22.07USD 13,722SEC filing ↗
2023-02-22COMMODORE CAPITAL LPPurchase (P)Common stock, par value $0.001 per share23,565USD 5.11USD 120,417SEC filing ↗
2023-02-21COMMODORE CAPITAL LPPurchase (P)Common stock, par value $0.001 per share8,194USD 5.25USD 43,018SEC filing ↗
2023-01-03Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.Purchase (P)Common Stock629,297USD 4.00USD 2,517,188SEC filing ↗
2022-12-09Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.Purchase (P)Common Stock19,299USD 3.93USD 75,845SEC filing ↗
2022-12-08Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.Purchase (P)Common Stock10,600USD 3.75USD 39,750SEC filing ↗
2022-10-24Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.Purchase (P)Common Stock26,460USD 3.91USD 103,459SEC filing ↗
2022-10-21Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.Purchase (P)Common Stock48,100USD 3.92USD 188,552SEC filing ↗
2022-10-20Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.Purchase (P)Common Stock11,342USD 3.95USD 44,801SEC filing ↗
2022-10-19Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.Purchase (P)Common Stock125,726USD 3.89USD 489,074SEC filing ↗
2022-10-18Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.Purchase (P)Common Stock234,799USD 3.76USD 882,844SEC filing ↗
2022-10-17Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.Purchase (P)Common Stock145,672USD 3.36USD 489,458SEC filing ↗
2022-06-16Leonard Braden MichaelPurchase (P)Common Stock83,199USD 1.11USD 92,351SEC filing ↗
2022-06-06Leonard Braden MichaelPurchase (P)Common Stock2,630USD 1.16USD 3,051SEC filing ↗
2022-06-03Leonard Braden MichaelPurchase (P)Common Stock30,800USD 1.14USD 35,112SEC filing ↗

Form 4 evidence

100 transaction lines in the latest 365-day window; 564 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-01Garland J. ScottSale (S)Common Stock13,000USD 46.67USD 606,719SEC filing ↗
2026-10-01Garland J. ScottOption exercise / conversion (M)Common Stock13,000USD 15.47USD 201,110SEC filing ↗
2026-09-17Hohl BenjaminSale (S)Common Stock6,018USD 50.35USD 303,016SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-01Garland J. ScottSale (S)Common Stock13,000USD 46.67USD 606,719SEC filing ↗
2026-10-01Garland J. ScottOption exercise / conversion (M)Common Stock13,000USD 15.47USD 201,110SEC filing ↗
2026-09-17Hohl BenjaminSale (S)Common Stock6,018USD 50.35USD 303,016SEC filing ↗
2026-09-17Hohl BenjaminOption exercise / conversion (M)Common Stock3,982USD 14.85USD 59,133SEC filing ↗
2026-09-17Collins Helen LouiseSale (S)Common Stock5,000USD 50.35USD 251,752SEC filing ↗
2026-09-17Collins Helen LouiseOption exercise / conversion (M)Common Stock5,000USD 2.48USD 12,400SEC filing ↗
2026-08-17Hohl BenjaminSale (S)Common Stock6,018USD 58.58USD 352,538SEC filing ↗
2026-08-17Collins Helen LouiseSale (S)Common Stock5,000USD 58.59USD 292,928SEC filing ↗
2026-08-17Collins Helen LouiseOption exercise / conversion (M)Common Stock5,000USD 2.48USD 12,400SEC filing ↗
2026-08-04Derynck Mika KSale (S)Common Stock158,795USD 60.21USD 9,561,047SEC filing ↗
2026-08-04Derynck Mika KOption exercise / conversion (M)Common Stock158,795USD 10.84USD 1,720,967SEC filing ↗
2026-07-17Hohl BenjaminSale (S)Common Stock6,018USD 52.64USD 316,777SEC filing ↗
2026-07-17Hohl BenjaminOption exercise / conversion (M)Common Stock1,072USD 2.48USD 2,659SEC filing ↗
2026-07-17Collins Helen LouiseSale (S)Common Stock5,000USD 52.67USD 263,370SEC filing ↗
2026-07-17Collins Helen LouiseOption exercise / conversion (M)Common Stock5,000USD 2.48USD 12,400SEC filing ↗
2026-07-06Kunkel Lori AnneSale (S)Common Stock10,000USD 50.49USD 504,865SEC filing ↗
2026-06-22ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLCSale (S)Common Stock860,123USD 45.36USD 39,014,046SEC filing ↗
2026-06-17Hohl BenjaminSale (S)Common Stock6,018USD 43.80USD 263,576SEC filing ↗
2026-06-17Hohl BenjaminOption exercise / conversion (M)Common Stock6,018USD 2.48USD 14,925SEC filing ↗
2026-06-17Collins Helen LouiseSale (S)Common Stock5,000USD 43.80USD 219,017SEC filing ↗
2026-06-17Collins Helen LouiseOption exercise / conversion (M)Common Stock5,000USD 2.48USD 12,400SEC filing ↗
2026-06-15ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLCSale (S)Common Stock281,408USD 45.02USD 12,668,988SEC filing ↗
2026-06-05Kunkel Lori AnneSale (S)Common Stock10,000USD 34.54USD 345,362SEC filing ↗
2026-05-18Collins Helen LouiseSale (S)Common Stock5,000USD 39.79USD 198,962SEC filing ↗
2026-05-18Collins Helen LouiseOption exercise / conversion (M)Common Stock5,000USD 2.48USD 12,400SEC filing ↗
2026-04-17Collins Helen LouiseSale (S)Common Stock5,000USD 47.67USD 238,364SEC filing ↗
2026-04-17Collins Helen LouiseOption exercise / conversion (M)Common Stock5,000USD 2.48USD 12,400SEC filing ↗
2026-03-25Collins Helen LouiseSale (S)Common Stock40,000USD 35.10USD 1,404,000SEC filing ↗
2026-03-25Collins Helen LouiseOption exercise / conversion (M)Common Stock40,000USD 2.48USD 99,200SEC filing ↗
2026-03-17Collins Helen LouiseSale (S)Common Stock5,000USD 27.76USD 138,800SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerELVN
CIK0001672619
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history564 transaction lines from 2020-03-12 to 2026-10-01
44 P purchase lines · 364 S sale lines · 156 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.